Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 March Therapy Molecular characteristics of MPN with associated autoimmune and inflammatory disease Read more
2022 February Clinical practice A promising combination of Venetoclax plus EPOCH-R for patients with Richter’s syndrome Read more
2022 February Clinical trials Usage of younger unmatched donors for allo-HCT improves some clinical outcomes in MDS patients Read more
2022 February Prevention Direct oral anti-coagulants prevent recurrent cancer-associated thrombosis Read more
Top
